Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.
Share or print this source review
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.
Clinical context remains essential
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
Renal guidance: 2.5 Recommended Dosage in Patients with Renal Impairment / 8.6 Renal Impairment
At CrCl below 30 mL/min or in ESRD, potent CYP3A inhibitors or inducers contraindicate maraviroc. In adults without such interacting drugs, postural hypotension on 300 mg twice daily warrants reduction to 150 mg twice daily. Consider use in this renal population only if alternatives are unavailable. Check concomitant drugs, age and orthostatic symptoms.
RDM74-selzentry-official-1 · Source locator: Renal guidance: 2.5 Recommended Dosage in Patients with Renal Impairment / 8.6 Renal Impairment
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
GlobalRPh Renal Dosing Master v7.4. Review the retrieval and revision dates attached to each source. Selecting a reference does not imply clinical verification.
